NMHM 2024
The FDA OMHHE observes NMHM to raise awareness of the importance of improving the health of racial and ethnic minorities and reducing health disparities.
Related Articles
FDA Direct Podcast: Episode 2
FDA Commissioner Makary talks with Kyle Diamantas, FDA Deputy Commissioner for Human Foods and Sanjula Jain-Nagpal, Associate Director of Policy & Research S…
NatureMills US Inc. Issues Allergy Alert on Undeclared Wheat, Milk, and Sesame in Rice Mixes, Soups, Spice Mixes, Porridge Mix, Papads and Vadam Products
NatureMills US Inc., based in Prosper, Texas, is recalling select products that were sold between December 1, 2023, and May 10, 2025, due to undeclared…
HHS, FDA Issue RFI on Deregulatory Plan to Lower Costs and Empower Providers
HHS, FDA Issue RFI on Deregulatory Plan to Lower Costs and Empower Providers
Ariana Sweets Inc. Issues Allergy Alert on Undeclared Sesame and Wheat in AFGHANI CORN BREAD (“Doda”)
May, 13, 2025, Ariana Sweets Inc. of Fremont, CA is recalling AFGHANI CORN BREAD “Doda” manufactured prior to 4/24/2025, because it may contain undeclared sesame…
FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as
FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal
FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as
FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal
FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCL
On May 14, 2025, the Food and Drug Administration granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis, AbbVie Inc.)
FDA approves belzutifan for pheochromocytoma or paraganglioma
On May 14, 2025, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) for adult and pediatric patients 12 years and older
FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCL
On May 14, 2025, the Food and Drug Administration granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis, AbbVie Inc.)
FDA approves belzutifan for pheochromocytoma or paraganglioma
On May 14, 2025, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) for adult and pediatric patients 12 years and older